It is important to note that a detailed analysis of study ZA-301, and subsequently reported to the FDA, showed that unlike the suppression of FSH with approved testosterone, Androxal exhibits an increased frequency of sexual activity as determined by reported sexual abstinence. The reduced abstinence period resulted in lower sperm concentrations in some men on Androxal. These findings support those previously reported in the literature that show daily ejaculation results in sperm counts of <50% of baseline after only four successive days of sexual activity.Study ZA-300 (Androxal Safety Study)
Repros Reports Preliminary Findings: Second Pivotal Study And 6-Month Safety Study Support Androxal(R) Approvability
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.